CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

July 31, 2025

Conditions
Primary Biliary Cholangitis (PBC)
Interventions
DRUG

2mg CS0159

Oral QD

DRUG

Placebo

Oral QD

Trial Locations (16)

100050

Beijing Friendship Hospital, Captail Medcial University, Beijing

100069

Beijing Youan Hostital, Captial Medical University, Beijing

100730

Peking Union Medical College Hospital, Beijing

200120

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

230001

The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei

310000

Shaoyifu Hospital of Zhejiang University Medical, Hangzhou

410011

The Seconed Xiangya Hospital of Central South University, Changsha

430022

Wuhan Union Hospital of China, Wuhan

510630

The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou

Unknown

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou

Henan Provincial People's Hospital, Zhengzhou

The Third People's Hospital of Zhenjiang, Zhenjiang

The First Bethune Hospital of Jilin University, Changchun

Qilu Hospital of Shandong University, Jinan

West China Hospital, Sichuan University, Chengdu

The First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
lead

Cascade Pharmaceuticals, Inc

OTHER

NCT05896124 - CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) | Biotech Hunter | Biotech Hunter